Preparation of Lir@BSA-PMF nanoparticles and verification of their cell functions

doi:10.16352/j.issn.1001-6325.2024.02.0235

Abstract

Abstract: Objective To synthesize bovine serum albumin(BSA)-loaded liraqlutide (Lir)-nanoparticles coated with platelet membrane fragments (PMF) using a“bottom-up” nano-engineering chemistry technique, and to evaluate their cyto-compatibility and potential function of anti-oxidative stress. Methods PMF was extracted as reported previously. Lir@BSA nanoparticles were prepared by self-assembly method. PMF was coated on the surface of Lir@BSA nanoparticles by co-extrusion to prepare Lir@BSA-PMF. The physical and chemical properties of Lir@BSA-PMF particles were characterized as particle size, Zeta potential, transmission electron microscopy and particle size stability. The encapsulation efficiency, loading efficiency and cumulative release efficiency of liraglutide were calculated by enzyme-linked immunosorbent assay. Further, SDS-PAGE was used to analyze whether there was a similar membrane protein distribution of platelet membrane on Lir@BSA-PMF bionicnanocarrier.CCK-8 assay was used to verify the biocompatibility of the materials. Reactive oxygen species (ROS) experiment was used to explore the effect of Lir@BSA-PMF on cell oxidative damage. The uptake of cells on Lir@BSA-PMF bionic nano capsules was verified by cell phagocytosis experiment. Results Lir@BSA-PMF nanoparticles had a stable particle size of 25 nm with a spherical morphology, and a Zeta potential value of -25.5 mV. The encapsulation efficiency, loading efficiency and cumulative release efficiency of liraglutide were 85.56%, 7.96% and 77.06%, respectively. SDS-PAGE analysis showed that the Lir@BSA-PMF bio-mimetic nano capsules retained the similar membrane protein distribution as platelet membrane. CCK-8 assay verified that the nanomaterials were non-cytotoxic. ROS results showed that Lir@BSA-PMF nanomaterials had obvious antioxidant properties. The results of cell phagocytosis showed that the cells had a good phagocytosis effect on Lir@BSA-PMF nanoparticles. Conclusions The nanoparticles Lir@BSA-PMF are successfully synthesized and have no effects on cells viability in vitro. The particles are taken up by cells and show a significant function of antioxidant damage.

Key words: platelet membrane fragments, liraglutide, nanoparticles, cell functions

CLC Number:

R737.14

HUANG Qingyu, CHEN Qiying, SUN Shengjia, WU Bangwei, LIN Shan, Alimujiang·MAIMAITIJIANG. Preparation of Lir@BSA-PMF nanoparticles and verification of their cell functions[J]. Basic & Clinical Medicine, 2024, 44(2): 235-241.

References

[1]Amelia R, Sari Wahyuni A, Yunanda Y, et al. Atherosclerotic cardiovascular disease in diabetes patients[J]. Curr Diabetes Rev, 2023, 19: 62-69.
[2]李沛城, 冯波. 利拉鲁肽下调糖尿病 ApoE^-/小鼠主动脉糖基化终产物受体表达并减轻动脉粥样硬化[J]. 中华内分泌代谢杂志, 2016, 32: 680-684.
[3]Jakhar DK, Vishwakarma VK, Singh R, et al. Fat fighting liraglutide based nano-formulation to reverse obesity: design, development and animal trials[J]. Int J Pharm, 2023, 634: 122585.doi:doi: 10.1016/j.ijpharm.2023.122585.
[4]Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles[J]. Nat Rev Clin Oncol, 2023, 20: 33-48.
[5]Chen L, Zhou Z, Hu C, et al. Platelet membrane-coated nanocarriers targeting plaques to deliver anti-CD47 antibody for atherosclerotic therapy[J]. Research, 2022, 2022:1-12.doi:doi: 10.34133/2022/9845459.
[6]郭方君, 杨人强. 血小板微粒促进动脉粥样硬化发生的研究进展[J]. 基础医学与临床, 2020, 40:1551-1555.
[7]Mei D, Gong L, Zou Y, et al. Platelet membrane-cloaked paclitaxel-nanocrystals augment postoperative chemotherapeutical efficacy[J]. J Control Release, 2020, 324: 341-353.
[8]Becker PH, Thérond P, Gaignard P. Targeting mitochondrial function in macrophages: a novel treatment strategy for atherosclerotic cardiovascular disease?[J]. Pharmacol Ther, 2023, 247: 108441.
[9]张文婷, 王瑾, 岳继萍, 等. 硫氧还蛋白相互作用蛋白降低GLP-1促小鼠胰岛β细胞的增殖效应[J]. 基础医学与临床, 2020, 40:1076-1082.
[10]刘东华, 荆凡波, 全香花, 等. 基因多态性与胰高血糖素样肽1受体激动剂疗效的相关性研究进展[J]. 中国药房, 2020, 31: 245-250.
[11]Wronka M, Krzemińska J, Mlłynarska E, et al. New insights into the use of liraglutide—impact on cardiovascular risk and microvascular outcomes[J]. Biomedicines, 2023, 11: 1159-1175.
[12]刘滔滔, 李天容, 王雪, 等. 纳米颗粒和外泌体靶向载药系统诊治动脉粥样硬化的机遇与挑战[J].中国全科医学, 2023, 26: 903-910.
[13]Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery[J]. Nat. Biotechnol, 2015, 33: 941-951.
[14]Lim GB. Pro-inflammatory atherogenic role of platelets[J]. Nat Rev Cardiol, 2020, 17: 6-7.
[15]Ferreira-Faria I, Yousefiasl S, Macário-Soares A, et al. Stem cell membrane-coated abiotic nanomaterials for biomedical applications[J]. J Control Release, 2022, 351: 174-197.